Emerging targets for antidepressant therapies
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Despite adequate antidepressant monotherapy, the majority of depressed patients do not achieve remission. Even optimal and aggressive therapy leads to a substantial number of patients who show minimal and often only transient improvement. In order to address this substantial problem of treatment-resistant depression, a number of novel targets for antidepressant therapy have emerged as a consequence of major advances in the neurobiology of depression. Three major approaches to uncover novel therapeutic interventions are: first, optimizing the modulation of monoaminergic neurotransmission; second, developing medications that act upon neurotransmitter systems other than monoaminergic circuits; and third, using focal brain stimulation to directly modulate neuronal activity. We review the most recent data on novel therapeutic compounds and their antidepressant potential. These include triple monoamine reuptake inhibitors, atypical antipsychotic augmentation, and dopamine receptor agonists. Compounds affecting extra-monoamine neurotransmitter systems include CRF1 receptor antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists, NMDA receptor antagonists, nemifitide, omega-3 fatty acids, and melatonin receptor agonists. Focal brain stimulation therapies include vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS), magnetic seizure therapy (MST), transcranial direct current stimulation (tDCS), and deep brain stimulation (DBS).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059 · cited 1×
“In this study, four patients improved significantly after six months of bilateral DBS targeting the subgenual cingulate white matter [173].”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“Despite adequate care with currently available treatments, up to 70% of depressed patients have residual symptoms [3], and, even with more aggressive therapies, 20% or more may show only a limited response [4].”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
STRESS AND HIPPOCAMPAL PLASTICITY
McEwen, B. S. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.105 · Cited by 2,087 · cited 1×
“glutamatergic neurotransmission may play a role in the pathophysiology of depression [83,84], and that stress-induced atrophy of hippocampal neurons in rodents may be attenuated by ionotropic glutamate receptor antagonists [85,86].”
Background(2003) · The Lancet · doi:10.1016/s0140-6736(03)12705-5 · Cited by 1,706
The role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378 · cited 2×
“Compared to nondepressed controls, depressed or depressed suicidal patients show increased HPA axis activity and elevated cerebrospinal fluid (CSF) CRF concentrations, increased paraventricular nucleus (PVN) CRF mRNA expression, and a larger number of CRF-expressing neurons in the PVN [58].”
BackgroundSelf-citationThe role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“Considerable effort has been targeted to DA circuits based on a growing database implicating DA dysfunction in the pathophysiology of depression [6].”
BackgroundSelf-citationMayberg, H. S. (2003) · British Medical Bulletin · doi:10.1093/bmb/65.1.193 · Cited by 1,166
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 1×
“Despite adequate care with currently available treatments, up to 70% of depressed patients have residual symptoms [3], and, even with more aggressive therapies, 20% or more may show only a limited response [4].”
BackgroundDeep Brain Stimulation to Reward Circuitry Alleviates Anhedonia in Refractory Major Depression
Schlaepfer, T. E., Cohen, M. X., Frick, C., Kosel, M., Brodesser, D., Axmacher, N., Joe, A. Y., Kreft, M., Lenartz, D., & Sturm, V. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301408 · Cited by 1,027 · cited 1×
“Other promising locations include the habenula [180], nucleus accumbens [181], and the thalamic peduncle [182].”
BackgroundDeep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression
Malone, D. A., Dougherty, D. D., Rezai, A. R., Carpenter, L. L., Friehs, G. M., Eskandar, E. N., Rauch, S. L., Rasmussen, S. A., Machado, A. G., Kubu, C. S., et al. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.029 · Cited by 897 · cited 1×
“A recent open-label DBS study in TRD patients that targeted the ventral capsule/ventral striatum region showed significant improvement in depressive symptoms in TRD patients, some of whom were followed longer than four years [179].”
BackgroundCalabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 1×
“Mono-therapy with the atypical antipsychotic quetiapine was also found to be safe and efficacious in the treatment of bipolar depression [51,52], leading to an FDA approval for this indication in 2006.”
BackgroundOmega 3 Fatty Acids in Bipolar Disorder: A Preliminary Double-blind, Placebo-Controlled Trial
Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S., Zboyan, H. A., Diamond, E., Cress, K. K., & Marangell, L. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.5.407 · Cited by 814
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death
Sapolsky, R. M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00971-9 · Cited by 699 · cited 1×
“glutamatergic neurotransmission may play a role in the pathophysiology of depression [83,84], and that stress-induced atrophy of hippocampal neurons in rodents may be attenuated by ionotropic glutamate receptor antagonists [85,86].”
BackgroundSackeim, H. A., Haskett, R. F., Mulsant, B. H., Thase, M. E., Mann, J. J., Pettinati, H. M., Greenberg, R. M., Crowe, R. R., Cooper, T. B., & Prudic, J. (2001) · JAMA · doi:10.1001/jama.285.10.1299 · Cited by 686
Nemets, B., Stahl, Z., & Belmaker, R. H. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.477 · Cited by 627
Vagus-nerve stimulation for the treatment of epilepsy
Ben-Menachem, E. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00220-x · Cited by 560
Thase, M. E., Macfadden, W., Weisler, R. H., Chang, W., Paulsson, B., Khan, A., & Calabrese, J. R. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248603.76231.b7 · Cited by 559 · cited 1×
“Mono-therapy with the atypical antipsychotic quetiapine was also found to be safe and efficacious in the treatment of bipolar depression [51,52], leading to an FDA approval for this indication in 2006.”
BackgroundMarcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518 · cited 1×
“Two, large randomized placebo-controlled trials have shown that augmentation with aripiprazole has antidepressant efficacy in patients unresponsive to standard antidepressants [36,37]; in November 2007, the FDA-approved aripiprazole for this indication.”
BackgroundLin, P.-Y., & Su, K.-P. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0712 · Cited by 481
Kellner, C. H., Knapp, R. G., Petrides, G., Rummans, T. A., Husain, M. M., Rasmussen, K., Mueller, M., Bernstein, H. J., O’Connor, K., Smith, G., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.12.1337 · Cited by 471
Glutamate and Depression: Clinical and Preclinical Studies
PAUL, I. A., & SKOLNICK, P. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.016 · Cited by 408
Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes
Nahas, Z., Marangell, L. B., Husain, M. M., Rush, A. J., Sackeim, H. A., Lisanby, S. H., Martinez, J. M., & George, M. S. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0902 · Cited by 390
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
George, M. S., Rush, A. J., Marangell, L. B., Sackeim, H. A., Brannan, S. K., Davis, S. M., Howland, R., Kling, M. A., Moreno, F., Rittberg, B., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.028 · Cited by 372 · cited 1×
“Twenty-seven percent of TRD patients in the VNS plus TAU group were responders based on HAMD scores compared to 13% of those in the TAU alone group [143].”
ResultArroll, B. (2005) · The Annals of Family Medicine · doi:10.1370/afm.349 · Cited by 351 · cited 1×
“Several randomized, double-blind, placebo-controlled trials demonstrate that medications that modulate monoaminergic neurotrans-mission possess antidepressant efficacy [5].”
BackgroundLisanby, S. H., Husain, M. M., Rosenquist, P. B., Maixner, D., Gutierrez, R., Krystal, A., Gilmer, W., Marangell, L. B., Aaronson, S., Daskalakis, Z. J., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.118 · Cited by 333 · cited 1×
“A recently published subanalysis of this data shows that active rTMS patients who failed only one antidepressant trial during the current episode improved significantly more than those who failed two to four adequate trials [164].”
BackgroundAn open label trial of C-1073 (mifepristone) for psychotic major depression*
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01432-4 · Cited by 320
Avery, D. H., Holtzheimer, P. E., Fawaz, W., Russo, J., Neumaier, J., Dunner, D. L., Haynor, D. R., Claypoole, K. H., Wajdik, C., & Roy-Byrne, P. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.003 · Cited by 318
Self-citationSu, K.-P., Huang, S.-Y., Chiu, T.-H., Huang, K.-C., Huang, C.-L., Chang, H.-C., & Pariante, C. M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0418 · Cited by 308 · cited 1×
“Omega-3 fatty acids may be useful in patients with perinatal depression as well [111], though results are mixed [112].”
Srinivasan, V., Smits, M., Spence, W., Lowe, A. D., Kayumov, L., Pandi-Perumal, S. R., Parry, B., & Cardinali, D. P. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970600571822 · Cited by 292
Jiménez, F., Velasco, F., Salin-Pascual, R., Hernández, J. A., Velasco, M., Criales, J. L., & Nicolini, H. (2005) · Neurosurgery · doi:10.1227/01.neu.0000170434.44335.19 · Cited by 291
Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.013 · Cited by 286 · cited 1×
“Aprepitant (MK-869) showed antidepressant efficacy in an initial placebo-controlled trial [74], but subsequent controlled studies failed to confirm this finding [78].”
BackgroundRapid Reversal of Psychotic Depression Using Mifepristone
Belanoff, J. K., Flores, B. H., Kalezhan, M., Sund, B., & Schatzberg, A. F. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00009 · Cited by 282
Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071199 · Cited by 254 · cited 1×
“CP-316 311, another CRF1 receptor antagonist, did not show significant antidepressant effects in a placebo-controlled and sertraline-controlled trial [63]; however, it is unclear whether the dose tested was sufficient to block CNS CRF1 receptors effectively.”
BackgroundDeep brain stimulation of the lateral habenula in treatment resistant major depression
Sartorius, A., & Henn, F. A. (2007) · Medical Hypotheses · doi:10.1016/j.mehy.2007.03.021 · Cited by 251
Risperidone Augmentation of Selective Serotonin Reuptake Inhibitors in Major Depression
Ostroff, R. B., & Nelson, J. C. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0410 · Cited by 248
Rogers, P. J., Appleton, K. M., Kessler, D., Peters, T. J., Gunnell, D., Hayward, R. C., Heatherley, S. V., Christian, L. M., McNaughton, S. A., & Ness, A. R. (2008) · British Journal of Nutrition · doi:10.1017/s0007114507801097 · Cited by 243
Dunner, D. L., Rush, A. J., Russell, J. M., Burke, M., Woodard, S., Wingard, P., & Allen, J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0501 · Cited by 234 · cited 1×
“The same is true with regard to the maintenance of response over an additional year with close to 65–77% of patients in the VNS plus TAU group maintaining their response [144] as compared to 38% of patients receiving TAU alone [145].”
ResultKeck, P. E., Mintz, J., McElroy, S. L., Freeman, M. P., Suppes, T., Frye, M. A., Altshuler, L. L., Kupka, R., Nolen, W. A., Leverich, G. S., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.056 · Cited by 234 · cited 1×
“A small number of placebo-controlled studies have failed to show antidepressant effects for omega-3 fatty acids [116–119].”
BackgroundBystritsky, A., Ackerman, D. L., Rosen, R. M., Vapnik, T., Gorbis, E., Maidment, K. M., & Saxena, S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0418 · Cited by 220 · cited 1×
“Some drugs in this class have shown efficacy in augmenting SSRI treatment of anxiety disorders, such as obsessive compulsive disorder (OCD) [16–18], post traumatic stress disorder (PTSD) [19– 21] and generalized anxiety disorder [22–24].”
Backgroundda Silva, T. M., Munhoz, R. P., Alvarez, C., Naliwaiko, K., Kiss, Á., Andreatini, R., & Ferraz, A. C. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.03.008 · Cited by 205 · cited 1×
“In patients with comorbid PD and MDD, a double-blind, randomized, placebo-controlled study showed that adding omega-3 fatty acids with and without antidepressants, resulted in statistically significant improvements in depressive symptoms [113].”
BackgroundVagus nerve stimulation for depression: efficacy and safety in a European study
Schlaepfer, T. E., Frick, C., Zobel, A., Maier, W., Heuser, I., Bajbouj, M., O'Keane, V., Corcoran, C., Adolfsson, R., Trimble, M., et al. (2008) · Psychological Medicine · doi:10.1017/s0033291707001924 · Cited by 205 · cited 1×
“Two open-label studies suggested an acute benefit for VNS in TRD patients [136] with longer duration of treatment associated with higher response rates [137– 139].”
BackgroundCorya, S. A., Williamson, D., Sanger, T. M., Briggs, S. D., Case, M., & Tollefson, G. (2006) · Depression and Anxiety · doi:10.1002/da.20130 · Cited by 170
Fitzgerald, P. B., Hoy, K., Daskalakis, Z. J., & Kulkarni, J. (2009) · Depression and Anxiety · doi:10.1002/da.20454 · Cited by 147 · cited 1×
“According to one randomized study, low-frequency and high-frequency rTMS were found to be equally effective in the treatment of depression [156].”
BackgroundMcIntyre, A., Gendron, A., & McIntyre, A. (2007) · Depression and Anxiety · doi:10.1002/da.20275 · Cited by 145
Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00003 · Cited by 140 · cited 1×
“Risperidone may also be effective as an adjunct in SSRI nonresponders as demonstrated in two randomized, double-blind, placebo-controlled trials [38,39] and in one trial measuring its antisuicidal effect [40].”
BackgroundMagnetic Seizure Therapy Improves Mood in Refractory Major Depression
Kosel, M., Frick, C., Lisanby, S. H., Fisch, H.-U., & Schlaepfer, T. E. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300293 · Cited by 136 · cited 1×
“Unlike ECT, however, it has fewer cognitive side effects [168–170].”
BackgroundRees, A.-M., Austin, M.-P., & Parker, G. B. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701827267 · Cited by 134 · cited 1×
“Omega-3 fatty acids may be useful in patients with perinatal depression as well [111], though results are mixed [112].”
Avery, D. H., Isenberg, K. E., Sampson, S. M., Janicak, P. G., Lisanby, S. H., Maixner, D. F., Loo, C., Thase, M. E., Demitrack, M. A., & George, M. S. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0315 · Cited by 129 · cited 1×
“An open-label extension of this study showed that after another six weeks of active rTMS in those who did not respond to the acute trial, 26% showed a response, and 11% were in remission [163].”
Anesthetic Considerations for Magnetic Seizure Therapy: A Novel Therapy for Severe Depression
White, P. F., Amos, Q., Zhang, Y., Stool, L., Husain, M. M., Thornton, L., Downing, M., McClintock, S., & Lisanby, S. H. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000221182.71648.a3 · Cited by 111
Keitner, G. I., Garlow, S. J., Ryan, C. E., Ninan, P. T., Solomon, D. A., Nemeroff, C. B., & Keller, M. B. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.003 · Cited by 108 · cited 1×
“Risperidone may also be effective as an adjunct in SSRI nonresponders as demonstrated in two randomized, double-blind, placebo-controlled trials [38,39] and in one trial measuring its antisuicidal effect [40].”
BackgroundSelf-citationPeet, M. (2003) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2003.08.020 · Cited by 103
Reeves, H., Batra, S., May, R. S., Zhang, R., Dahl, D. C., & Li, X. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0805 · Cited by 102
Ropinirole in treatment-resistant depression: a 16-week pilot study
Cassano, P., Lattanzi, L., Fava, M., Navari, S., Battistini, G., Abelli, M., & Cassano, G. B. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000612 · Cited by 73
Cited by
Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579
“Additionally, studies exploring the effects of glutamatergic compounds in the treatment of depression show promising initial results (McEwen et al. 2010; Rakofsky et al., 2009).”
ResultLinking Molecules to Mood: New Insight Into the Biology of Depression
Krishnan, V., & Nestler, E. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.10030434 · Cited by 643
The neurobiology of depression and antidepressant action
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.007 · Cited by 519
Alcaro, A., Panksepp, J., Witczak, J., Hayes, D. J., & Northoff, G. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.11.023 · Cited by 144
“corticotropin-releasing factor and substance P) play a key role in the pathophysiology of depression (Nemeroff, 1996; Rakofsky et al., 2009; Thakker-Varia and Alder, 2009); their mechanism of action may include a rebalancing of amino acid neurotransmitter function (Skorzewska et al.”
Thyroid Function Within the Normal Range and the Risk of Depression: A Population-Based Cohort Study
Medici, M., Direk, N., Visser, W. E., Korevaar, T. I. M., Hofman, A., Visser, T. J., Tiemeier, H., & Peeters, R. P. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3589 · Cited by 123
Metadata
- Authors
- Rakofsky, J. J., Holtzheimer, P. E., & Nemeroff, C. B.
- Venue
- Current Opinion in Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 13
- Issue
- 3
- Pages
- 291-302
- ISSN
- 1367-5931 (ISSN-L)
- OpenAlex
- W2027722686
- Cited by
- 72
- References
- 56
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.